ArticleEuropean Medical Journal (Chelmsford, England)2019
Bronchopulmonary Dysplasia: An Update on Experimental Therapeutics.
Article in European Medical Journal (Chelmsford, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Vitamin A supplementation prevents the bronchopulmonary dysplasia in premature infants: A systematic review and meta-analysis.Medicine · 2021Pooled it
- Trial
- The Inflammatory Nexus of Bronchopulmonary Dysplasia: From Molecular Pathways to Precision Therapeutics.Mediators of inflammation · 2026Review
- Sex, hormones, and lung health.Physiological reviews · 2026Review
- Vitamin A and Its Related Diseases.Food science & nutrition · 2025Review
- Comprehensive pulmonary function analysis identifies predominant obstructive phenotype in former premature infants around one year of age.Pediatric pulmonology · 2024Article
- Outcomes of postnatal systemic corticosteroids administration in ventilated preterm newborns: a systematic review of randomized controlled trials.Frontiers in pediatrics · 2024Review
- Influence of inhaled nitric oxide on bronchopulmonary dysplasia in preterm infants with PPHN or HRF at birth: a propensity score matched study.Frontiers in pharmacology · 2024Article
- Respiratory-syncytial virus immunoprophylaxis on asthma symptoms development in prematurity with bronchopulmonary dysplasia.The journal of allergy and clinical immunology. Global · 2023Article
- Early Energy Intake and Amino Acid Profile in Preterm Newborns: A Quasi-Experimental Study.Nutrients · 2023Article
- Neurotrophins: Expression of Brain-Lung Axis Development.International journal of molecular sciences · 2023Review
- Vascular Endothelial Growth Factor as Molecular Target for Bronchopulmonary Dysplasia Prevention in Very Low Birth Weight Infants.International journal of molecular sciences · 2023Review
- Genetic and Biochemical Predictors of Neonatal Bronchopulmonary Dysplasia.Journal of pediatric genetics · 2022Article
- Early Salivary miRNA Expression in Extreme Low Gestational Age Newborns.Life (Basel, Switzerland) · 2022Article
- All trans-retinoic acid modulates hyperoxia-induced suppression of NF-kB-dependent Wnt signaling in alveolar A549 epithelial cells.PloS one · 2022Article
- Role of the LRP1-pPyk2-MMP9 pathway in hyperoxia-induced lung injury in neonatal rats.Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2021Article
- Complementary Feeding and Growth in Infants Born Preterm: A 12 Months Follow-Up Study.Children (Basel, Switzerland) · 2021Article
- Early Enteral Feeding Improves Tolerance of Parenteral Nutrition in Preterm Newborns.Nutrients · 2021Observational
- Effects of early energy intake on neonatal cerebral growth of preterm newborn: an observational study.Scientific reports · 2021Observational
- Neonatal Hyperglycemia Related to Parenteral Nutrition Affects Long-Term Neurodevelopment in Preterm Newborn: A Prospective Cohort Study.Nutrients · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Bronchopulmonary dysplasia (BPD) is a chronic inflammatory lung disease that affects thousands of newborns and infants every year. Although it is accepted that BPD results from lung damage and inflammation triggered by mechanical ventilation and hyperoxia, the causes and molecular events leading to lung damage and arrested development remain unknown. While recent advances in neonatal care have improved the survival of very low-weight infants, the rates of BPD have not improved accordingly. This is mainly due to our limited understanding of the disease's pathogenesis and the effective therapeutic options available. Current therapeutics for BPD involve ventilation management, steroid treatment, and administration of various agents, such as pulmonary surfactant, caffeine, vitamin A, nitric oxide, and stem cells. However, the efficacy of these agents in preventing and ameliorating BPD symptoms varies depending on the populations studied and the disease stage. As the field moves towards personalised therapeutic approaches, this review summarises clinical and experimental studies conducted in various models, aiming to increase understanding of the cellular and molecular mechanisms by which these agents can prevent or treat BPD. Due to the increasing number of extremely premature infants, it is imperative that we continue to work towards understanding the mechanisms of BPD pathogenesis and generating more effective therapeutic options.
Indexed as
Identifiers
31372499PMC6673641W2982559414What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.